Following recent tensions over drug pricing and access raised questions about the UK’s long-term appeal for pharmaceutical innovation, new policy developments suggest the country may be quietly gaining leverage in a broader global contest.
According to analysis from GlobalData, recent UK–US policy moves — combined with mounting uncertainty around US manufacturing requirements — are beginning to reshape how pharmaceutical companies think about investment, launch sequencing, and supply chain strategy on both sides of the Atlantic.
In December 2025, the UK announced a landmark pharmaceuticals agreement with the US that grants UK-manufactured medicines and medical technologies tariff-free access to the US market for at least three years. The deal arrived alongside domestic reforms aimed at improving access to innovative therapies, including a roughly 25 percent increase in net NHS spending on innovative medicines and higher cost-effectiveness thresholds for the National Institute for Health and Care Excellence (NICE).
The UK-US deal was seen as a favourable outcome for the British life sciences scene. For example, the European Union agreed to pay the US a tariff rate of 15 percent for pharmaceuticals as part of a trade deal agreed in July 2025.
“Zero-tariff access to the US, combined with more predictable and generous domestic pricing, gives the UK a rare structural advantage in attracting early launches, clinical trials, and high-value manufacturing,” said Edita Hamzic, Healthcare Analyst at GlobalData, in the press release.
Policy durability over price
For multinational drugmakers, the appeal may lie less in headline pricing than in predictability. GlobalData notes that investment decisions are increasingly shaped by policy durability rather than cost alone — a shift that reflects growing concern over regulatory and trade volatility in the US.
Under the Trump administration, companies face deadlines to fulfill “most-favored nation” (MFN) commitments, which require manufacturers to transfer US consumption-related production to domestic facilities in exchange for three-year tariff exemptions. While nearly $500 billion in US research and development and manufacturing investment has been pledged outside MFN deals, uncertainty surrounding Section 232 investigations and potential future tariffs continues to complicate long-term planning.
Recent events have underscored those risks. Novo Nordisk received an FDA warning letter over cGMP violations at its Bloomington, Indiana facility, highlighting the regulatory scrutiny attached to US-based production. Meanwhile, several companies, including Eli Lilly, Novartis, and GSK, have pledged to spend billions to increase their operations in the US.
While these investments reaffirm the US’s unmatched scale, they also illustrate the capital intensity — and execution risk — associated with concentrating manufacturing in a single jurisdiction.
A near-term opening for the UK?
Against this backdrop, the UK’s strategy appears more tactical than ideological — positioning itself as a stable bridge between US market access and manageable domestic pricing.
UK ministers have already pointed to multi-billion-pound commitments from Moderna, Bristol Myers Squibb, and BioNTech as early signs that tariff certainty and pricing reform are strengthening confidence in the UK as both an R&D and manufacturing base.
Chris Boerner, Bristol Myers Squibb CEO, said, “Based on the UK commitments and increased investment in innovative medicines underpinning this agreement, BMS anticipates being able to invest upwards of $500 million over the next 5 years.”
For GlobalData, the implications extend beyond originator companies. “For CDMOs, this environment favors flexible, multi-region capabilities, as sponsors prioritize resilience and optionality over single-market concentration,” Hamzic said.
Strategic implications
The emerging picture is not one of simple competition between the UK and US, but of a more fragmented, policy-driven investment landscape. Companies are increasingly hedging — diversifying manufacturing, staging launches, and seeking jurisdictions that offer speed, regulatory clarity, and political stability.
Whether the UK can translate this moment into durable advantage remains an open question. Much will depend on whether pricing reforms deliver meaningful access gains without reigniting tensions over affordability, and whether tariff arrangements evolve into longer-term trade certainty.
What is clear, however, is that the UK’s pharmaceutical strategy can no longer be viewed in isolation. As US trade, pricing, and manufacturing policies ripple outward, they are reshaping global investment decisions — and, for now at least, creating an unexpected opening for the UK.
